DK1414828T3 - Antitumoranaloger - Google Patents

Antitumoranaloger

Info

Publication number: DK1414828T3
Authority: DK; Denmark
Prior art keywords: antitumor; analogues; ecteinascidin; derivatives; antitumor analogues
Prior art date: 2001-08-07

Application number

DK02753134T

Other languages

English (en)

Inventor

Valentin Martinez

Pilar Gallego

Carmen Cuevas

Simon Munt

Ignacio Manzanares

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-07

Filing date

2002-08-06

Publication date

2008-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9919954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1414828(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-06 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2008-02-04 Application granted granted Critical

2008-02-04 Publication of DK1414828T3 publication Critical patent/DK1414828T3/da

Links

230000000259 anti-tumor effect Effects 0.000 title 1
PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical class C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)

DK02753134T 2001-08-07 2002-08-06 Antitumoranaloger DK1414828T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0119243.4A GB0119243D0 (en)	2001-08-07	2001-08-07	Antitumoral analogs of ET-743
PCT/GB2002/003592 WO2003014127A1 (en)	2001-08-07	2002-08-06	Antitumoral analogs

Publications (1)

Publication Number	Publication Date
DK1414828T3 true DK1414828T3 (da)	2008-02-04

Family

ID=9919954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02753134T DK1414828T3 (da)	2001-08-07	2002-08-06	Antitumoranaloger

Country Status (22)

Country	Link
US (1)	US7763615B2 (da)
EP (3)	EP1806349A1 (da)
JP (2)	JP4684552B2 (da)
KR (1)	KR20040032150A (da)
CN (1)	CN100334094C (da)
AT (1)	ATE374777T1 (da)
AU (1)	AU2002313540B2 (da)
CA (1)	CA2455768C (da)
CY (1)	CY1107830T1 (da)
DE (1)	DE60222775T2 (da)
DK (1)	DK1414828T3 (da)
ES (1)	ES2294151T3 (da)
GB (1)	GB0119243D0 (da)
HU (1)	HU229779B1 (da)
IL (2)	IL160051A0 (da)
MX (1)	MXPA04001240A (da)
NO (1)	NO337476B1 (da)
NZ (1)	NZ530837A (da)
PL (1)	PL218295B1 (da)
PT (1)	PT1414828E (da)
RU (1)	RU2283842C2 (da)
WO (1)	WO2003014127A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0202544D0 (en) *	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
BRPI0907122B8 (pt)	2008-01-11	2021-05-25	Albany Molecular Res Inc	compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
WO2011003007A1 (en) *	2009-07-01	2011-01-06	Albany Molecular Research, Inc.	Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) *	2009-07-01	2011-01-06	Albany Molecular Research, Inc.	Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US8637501B2 (en) *	2009-07-01	2014-01-28	Albany Molecular Research, Inc.	Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) *	2009-07-01	2015-07-07	Albany Molecular Research, Inc.	Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
AU2011257277B2 (en) *	2010-05-25	2016-02-25	Pharma Mar, S.A.	Synthetic process for the manufacture of ecteinascidin compounds
BR112013012814B1 (pt)	2010-10-26	2019-10-08	Nec Corporation	Dispositivo de decodificação de vídeo e método de decodificação de vídeo
DK2786753T3 (da) *	2010-11-12	2019-04-15	Pharma Mar Sa	Kombinationsterapi med et antitumorantibiotikum
WO2012088124A2 (en)	2010-12-21	2012-06-28	Albany Molecular Research, Inc.	Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en)	2010-12-21	2012-06-28	Albany Molecular Research, Inc.	Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
CN108271369A (zh)	2015-10-23	2018-07-10	法尔玛赞公司	用于制备色胺及其衍生物的新工艺
US11332480B2 (en) *	2017-04-27	2022-05-17	Pharma Mar, S.A.	Antitumoral compounds
TWI824043B (zh) *	2018-10-25	2023-12-01	西班牙商瑪製藥股份有限公司	藥物抗體共軛物
CA3148690A1 (en)	2019-09-03	2021-03-11	Ioannis METAXAS	Lurbinectedin in the treatment of malignant mesothelioma
CN112574234B (zh) *	2019-09-27	2022-05-24	江苏恒瑞医药股份有限公司	一种海鞘素衍生物的制备方法
WO2021098992A1 (en)	2019-11-21	2021-05-27	Pharma Mar, S.A.	Methods of treating small cell lung cancer with lurbinectedin formulations
WO2021228414A1 (en)	2020-05-14	2021-11-18	Pharma Mar, S.A.	Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) *	2019-11-21	2023-09-27	Pharma Mar Sa	Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
CA3175426A1 (en)	2020-04-21	2021-10-28	Alfonso Latorre Lozano	Drug antibody conjugates
TW202144369A (zh) *	2020-04-26	2021-12-01	大陸商江蘇恆瑞醫藥股份有限公司	海鞘素類衍生物及其製備方法與醫藥用途
AU2020466790B2 (en) *	2020-09-04	2025-07-10	Pharma Mar, S.A.	Combination of lurbinectedin and immune checkpoint inhibitor
WO2022101255A1 (en)	2020-11-10	2022-05-19	Pharma Mar, S.A.	Lurbinectedin and irinotecan combinations
IN202141039393A (da) *	2021-08-31	2023-03-03
AU2022381992A1 (en)	2021-11-08	2024-05-16	Pharma Mar, S.A.	Lurbinectedin and atezolizumab combinations
CN115246846B (zh) *	2021-11-19	2024-10-01	江苏慧聚药业股份有限公司	卢比替定新晶型及其制备
CN115304619A (zh) *	2022-04-08	2022-11-08	上海皓元医药股份有限公司	一种卢比替定的晶型及其制备方法
CN114940682A (zh) *	2022-05-18	2022-08-26	博瑞制药(苏州)有限公司	芦比替定的晶型及其制备方法和用途
WO2024186263A1 (en) *	2023-03-07	2024-09-12	Axcynsis Therapeutics Pte. Ltd.	Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2024188978A1 (en)	2023-03-10	2024-09-19	Pharma Mar, S.A.	Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
WO2025059336A1 (en) *	2023-09-13	2025-03-20	Navinta, Llc	An improved process for preparation of lurbinectedin
CN121986103A (zh)	2023-10-09	2026-05-05	法马马有限公司	用于制造海鞘素化合物的合成方法
EP4563149A1 (en)	2023-11-30	2025-06-04	Pharma Mar, S.A.	Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
TW202532075A (zh) *	2024-02-08	2025-08-16	大陸商映恩生物製藥（蘇州）有限公司	海鞘素類化合物及其應用
WO2026022359A2 (en)	2024-07-26	2026-01-29	Pharma Mar, S.A.	Synthetic process for the manufacture of ecteinascidin compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59225189A (ja)	1983-06-03	1984-12-18	Shionogi & Co Ltd	キノナミン誘導体およびその製造法
JPS6084288A (ja)	1983-10-13	1985-05-13	Shionogi & Co Ltd	シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en)	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en)	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en)	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
AU589282B2 (en)	1986-06-09	1989-10-05	University Of Illinois	Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5478932A (en)	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
US5721362A (en)	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
US5985876A (en) *	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CZ301083B6 (cs) *	1998-04-06	2009-11-04	The Board Of Trustees Of The University Of Illinois	Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
KR100643092B1 (ko)	1998-05-11	2006-11-10	파르마 마르, 에스.에이.	엑테인아시딘 743의 대사산물
US6124292A (en) *	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
AR035842A1 (es) *	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
JP2003520801A (ja) *	2000-01-19	2003-07-08	ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク	サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
JP5219323B2 (ja) *	2000-04-12	2013-06-26	ファルマ・マール・ソシエダード・アノニマ	抗腫瘍性エクチナサイジン誘導体
MXPA02011319A (es) *	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.

2001
- 2001-08-07 GB GBGB0119243.4A patent/GB0119243D0/en not_active Ceased
2002
- 2002-08-06 EP EP07001308A patent/EP1806349A1/en not_active Ceased
- 2002-08-06 IL IL16005102A patent/IL160051A0/xx unknown
- 2002-08-06 MX MXPA04001240A patent/MXPA04001240A/es active IP Right Grant
- 2002-08-06 WO PCT/GB2002/003592 patent/WO2003014127A1/en not_active Ceased
- 2002-08-06 EP EP10180740A patent/EP2270018A1/en not_active Withdrawn
- 2002-08-06 DE DE60222775T patent/DE60222775T2/de not_active Expired - Lifetime
- 2002-08-06 CA CA2455768A patent/CA2455768C/en not_active Expired - Lifetime
- 2002-08-06 PT PT02753134T patent/PT1414828E/pt unknown
- 2002-08-06 RU RU2004106617/04A patent/RU2283842C2/ru active
- 2002-08-06 US US10/485,536 patent/US7763615B2/en active Active
- 2002-08-06 NZ NZ530837A patent/NZ530837A/en not_active IP Right Cessation
- 2002-08-06 KR KR10-2004-7001924A patent/KR20040032150A/ko not_active Ceased
- 2002-08-06 CN CNB028196511A patent/CN100334094C/zh not_active Expired - Lifetime
- 2002-08-06 DK DK02753134T patent/DK1414828T3/da active
- 2002-08-06 AT AT02753134T patent/ATE374777T1/de active
- 2002-08-06 HU HU0401174A patent/HU229779B1/hu unknown
- 2002-08-06 ES ES02753134T patent/ES2294151T3/es not_active Expired - Lifetime
- 2002-08-06 PL PL367940A patent/PL218295B1/pl unknown
- 2002-08-06 JP JP2003519076A patent/JP4684552B2/ja not_active Expired - Lifetime
- 2002-08-06 EP EP02753134A patent/EP1414828B9/en not_active Expired - Lifetime
- 2002-08-06 AU AU2002313540A patent/AU2002313540B2/en active Active
2004
- 2004-01-26 IL IL160051A patent/IL160051A/en active IP Right Grant
- 2004-03-05 NO NO20040961A patent/NO337476B1/no not_active IP Right Cessation
2007
- 2007-12-12 CY CY20071101576T patent/CY1107830T1/el unknown
2010
- 2010-09-17 JP JP2010209928A patent/JP2011026331A/ja active Pending

Also Published As

Publication number	Publication date
ES2294151T3 (es)	2008-04-01
IL160051A0 (en)	2004-06-20
CA2455768A1 (en)	2003-02-20
JP4684552B2 (ja)	2011-05-18
DE60222775T2 (de)	2008-07-17
GB0119243D0 (en)	2001-10-03
IL160051A (en)	2012-01-31
RU2283842C2 (ru)	2006-09-20
WO2003014127A1 (en)	2003-02-20
PT1414828E (pt)	2007-12-27
DE60222775D1 (de)	2007-11-15
HUP0401174A3 (en)	2005-12-28
MXPA04001240A (es)	2004-06-03
CN100334094C (zh)	2007-08-29
EP1414828B9 (en)	2008-02-20
HUP0401174A2 (hu)	2005-09-28
ATE374777T1 (de)	2007-10-15
US20060128711A1 (en)	2006-06-15
PL367940A1 (en)	2005-03-07
NZ530837A (en)	2005-07-29
HK1065786A1 (en)	2005-03-04
CA2455768C (en)	2011-10-11
US7763615B2 (en)	2010-07-27
PL218295B1 (pl)	2014-11-28
JP2005501093A (ja)	2005-01-13
KR20040032150A (ko)	2004-04-14
RU2004106617A (ru)	2005-04-10
EP2270018A1 (en)	2011-01-05
AU2002313540B2 (en)	2008-05-22
JP2011026331A (ja)	2011-02-10
HU229779B1 (en)	2014-07-28
EP1806349A1 (en)	2007-07-11
EP1414828B1 (en)	2007-10-03
NO337476B1 (no)	2016-04-18
NO20040961L (no)	2004-03-05
EP1414828A1 (en)	2004-05-06
CY1107830T1 (el)	2013-06-19
CN1564822A (zh)	2005-01-12

Publication	Publication Date	Title
PL367940A1 (en)	2005-03-07	Antitumoral analogs
SV2003001076A (es)	2003-07-29	Compuestos y procedimientos antitumorales ref. x-14776
NO20042279L (no)	2004-06-02	Kinazolinderivater som antitumormidler
CY1108707T1 (el)	2014-04-09	Αναλογα νοσισεπτινης
NO20014759L (no)	2001-11-29	C(7)-estersubstituerte taxaner som antitumormidler
NO20015477L (no)	2002-01-11	4,5,6,7-tetrahydroindazolderivater som antitumormidler
DK1385514T3 (da)	2009-01-19	Spiroinden- og spiroindanforbindelser
PT960107E (pt)	2003-02-28	Compostos de paclitaxel 6-tio-substituidos
BR0308452A (pt)	2006-06-06	composições farmacêuticas e métodos de preparação de composição farmacêutica
CY1108454T1 (el)	2014-04-09	Ενωσεις σπειροπυραζολιου
DE60135919D1 (de)	2008-11-06	Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
CY1108456T1 (el)	2012-05-23	Ενωσεις βενζιμιδαζολονης
CY1106247T1 (el)	2011-06-08	Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
ATE297904T1 (de)	2005-07-15	Halo-alkoxycarbonylverbindungen
SV2003000981A (es)	2003-07-29	Fenil-heterociclil-eteres ref. pcs10973
DE60025494D1 (de)	2006-04-06	Epothilon zusammensetzungen
NO20014755L (no)	2001-11-29	C(7)-karbonatsubstituerte taxaner som antitumormidler
BR0104352A (pt)	2002-01-02	Taxanos substituìdos por c10 carbamoilóxi como agentes antitumorais
DK1165549T3 (da)	2008-08-11	C7 carbamoyloxy-substituerede taxaner som antitumormidler
YU83903A (sh)	2006-08-17	Farmaceutske kombinacije zasnovane na derivatima piridoindolona
PT1011329E (pt)	2004-01-30	Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
ATE282611T1 (de)	2004-12-15	Stolonoxide
ATE478155T1 (de)	2010-09-15	Glycopeptidantibiotika
DE69926019D1 (de)	2005-08-04	G.723.1 audiokodierer
ECSP993288A (es)	2001-08-27	ACTIVADORES DE hPPARy y hPPARa